Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 20, 2016

Vetter Plans Expansion in Illinois

The company plans to purchase and develop an 18-acre site in Des Plaines, Illinois.

During a meeting held on July 12, 2016, Vetter Pharma shared its potential plan to purchase and develop an 18-acre site located in Des Plaines, Illinois. According to the company, the intention of this expansion is to offer its global customer base a US manufacturing opportunity.

For this project, Vetter plans to invest approximately $320 million in construction and site improvements in a more than 10-year period. Once it has reached its final expansion stage, the 18-acre site would include 1,138,237 square feet of facility space. If approved, the facility would be the company’s second US manufacturing site. The Des Plaines facility would lead to the possible creation of between 400–­500 jobs by the final expansion stage, Vetter noted.

Source: Vetter Pharma

 


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.